Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:6617's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.36 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Gongwin Biopharm Holdings Co (ROCO:6617) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gongwin Biopharm Holdings Co Forward Dividend Yield % Related Terms
ROCO:6617 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Gongwin Biopharm Holdings Co (ROCO:6617) has a Forward Dividend Yield % of 0.00% as of Jul. 21, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Gongwin Biopharm Holdings Co and its competitors. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 149 companies in the Biotechnology industry.
Is Gongwin Biopharm Holdings Co's Forward Dividend Yield % too high?
Gongwin Biopharm Holdings Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Gongwin Biopharm Holdings Co in the lower half of its industry. The industry median Forward Dividend Yield % is 1.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.36, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co (ROCO:6617) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$151.75, compared to a current price of NT$103.00 — trading 32.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Gongwin Biopharm Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Forward Dividend Yield % is 0.00% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued.
The current stock price of NT$103.00 is trading 32.1% below its estimated GF Value™ of NT$151.75.
GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.
Key valuation signals for ROCO:6617:
Forward Dividend Yield %: 0.00%
GF Value™: NT$151.75 vs. price of NT$103.00 (32.1% below fair value)
No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score
Get the complete analysis for ROCO:6617
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
